What is HC Wainwright's Estimate for Oculis Q1 Earnings?

Oculis Holding AG (NASDAQ:OCS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Oculis in a research note issued on Monday, May 12th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis' Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.40) EPS.

Other equities research analysts have also recently issued reports about the company. Robert W. Baird boosted their price target on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research note on Thursday, March 13th. Chardan Capital boosted their price target on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, May 9th.

Oculis Stock Performance

Shares of NASDAQ:OCS traded down $0.45 during trading on Tuesday, reaching $17.85. 11,835 shares of the stock were exchanged, compared to its average volume of 43,592. Oculis has a 12 month low of $10.79 and a 12 month high of $23.08. The firm has a market cap of $779.37 million, a PE ratio of -9.25 and a beta of 0.27. The stock has a 50-day moving average price of $17.94 and a 200-day moving average price of $18.41. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OCS. Bellevue Group AG acquired a new position in shares of Oculis during the fourth quarter worth $170,000. XTX Topco Ltd acquired a new position in shares of Oculis during the fourth quarter worth $225,000. Kestra Private Wealth Services LLC acquired a new position in shares of Oculis during the first quarter worth $234,000. Geode Capital Management LLC increased its holdings in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after buying an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Oculis during the fourth quarter worth $389,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.